Market capitalization | $15.35m |
Enterprise Value | $10.62m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 3.59 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-19.13m |
Free Cash Flow (TTM) Free Cash Flow | $-18.88m |
Cash position | $5.87m |
As a Free StocksGuide user, you can view scores for all 6,804 stocks worldwide.
4 Analysts have issued a Celsion Corporation forecast:
4 Analysts have issued a Celsion Corporation forecast:
Dec '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.72 -0.72 |
-
|
|
EBITDA | -18 -18 |
9%
9%
|
EBIT (Operating Income) EBIT | -19 -19 |
9%
9%
|
Net Profit | -19 -19 |
5%
5%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Celsion Corp . is a clinical stage oncology drug company. It focuses on cancer treatments, including directed chemotherapies, DNA-mediated immunotherapy and RNA-based therapies. The firm engages in the research and development of pharmaceutical products for cancer treatments. Its portfolio includes deoxyribonucleic acid-mediated immunotherapy and ribonucleic acid-based therapies. It operates through the Celsion and ThermoDox brands. The company was founded by Yim-Pan Cheung in 1982 and is headquartered in Lawrenceville, NJ.
Head office | United States |
CEO | Stacy Lindborg |
Employees | 25 |
Founded | 1982 |
Website | imunon.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.